83 results about "Plasma cholesterol" patented technology

PCT No. PCT/US97/06725 Sec. 371 Date Aug. 10, 1998 Sec. 102(e) Date Aug. 10, 1998 PCT Filed Apr. 21, 1997 PCT Pub. No. WO97/44314 PCT Pub. Date Nov. 27, 1997The instant invention is new compounds of Formula I their use as cerebrovascular agents in diseases such as stroke, peripheral vascular disease, restenosis, and as agents for regulating plasma cholesterol concentrations, for treating hypercholesterolemia and atherosclerosis, and for lowering the serum or plasma level of Lp(a). A pharmaceutical composition is also claimed.

The present invention provides peptidomimetics derived from Apolipoprotein A-I, which is useful for beneficially influencing lipid parameters and/or plasma cholesterol levels. The invention also provides pharmaceutical compositions and methods of treatment for elevated levels of plasma cholesterol.

A method is disclosed for determining whether a compound binds to a lipoprotein such as LDL or VLDL in a manner which will lower plasma cholesterol. The method provided includes assessing the ability of the compound to form a complex with the lipoprotein, and then determining whether the newly formed complex causes a change in the structure of apoB-100 that results in increased binding affinity to an LDL receptor.

The invention provides novel health care oil and belongs to edible oil. The health care oil is formed by mixing fish oil with vegetable oil, the using quantity of the fish oil is 3-60% of the weight of the vegetable oil, and the vegetable oil is one or more of soybean oil, peanut oil, corn germ oil, sunflower seed oil, olive oil, sesame oil, cottonseed oil and the like. As for the health care oil, the fish oil and the vegetable oil are mixed together, the fish oil is added into food during the cooking process, the uptake of the fish oil can be conveniently realized, the health care oil can be easily accepted by old people and children, and the problem of forgetting to eat can be simultaneously avoided. For the children, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) contained in the fish oil are polyunsaturated fatty acids, thereby improving the brain capacity and enhancing the memory and understanding facility. For the old people, by adopting the novel health care oil, arteriosclerosis can be slowed down, hypercholesterolemia, plasma cholesterol and triglycerides can be reduced, and the concentration of plasma lipoprotein, the blood viscosity and the blood pressure can be reduced.

This invention provides cholesterol absorption inhibitors of Formula I:

and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.

This invention provides cholesterol absorption inhibitors of Formula I:

and the pharmaceutically acceptable salts thereof, wherein R¹² is an alkyl, alkeny or alkynyl group mono- or poly-substituted with —OH, —COOH or a combination of—OH and —COOH, and R⁹ contains an alkyl, alkeny or alkynyl group substituted with a heterocyclic ring, amino or sulfonyl. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events.

The invention discloses an isoquinoline derivant. The said derivant, with 9,10-dimethoxy -[1,3] dioxide [4,5-g] isoquinoline [3,2-a] isoquinoline -7-ylidehydrochlorate (I) as its representative, reduces plasma cholesterol level by massively absorbing low density lipoprotein cholesterol and changing them to bile acid in liver. The 9,10-dimethoxy -[1,3] dioxide [4,5-g] isoquinoline [3,2-a] isoquinoline-7-ylidehydrochlorate is a new cholesterol lowering compound which is different in cholesterol lowering mechanism from statins. The 9,10-dimethoxy -[1,3] dioxide [4,5-g] isoquinoline [3,2-a] isoquinoline -7-ylidehydrochlorate and other isoquinoline derivants have an extremely low side toxiceffect, so they are safe natural cholesterol lowering compounds.

The invention relates to the use of pepper amide compound in preparation of drug or healthcare product for reducing blood fat with the general formula (I), wherein R, R1, R2 are defined in the specification, the piperamide compounds represented by formula (1) have the actions of substantially reducing cholesterin, triglyceride and increasing high density lipoprotein, fully activating lecithin cholesterol acyl transferase, forwarding extra-hepatic tissue cholesterol to liver, cleaning out plasma lipoproteins, plasma cholesterol and cholesterol esters, thus can be applied to the prevention and treatment of cardiovascular and cerebrovascular diseases, such as atherosclerotic, cerebrovascular, coronary artery and peribiliary vessel pathology and hyperlipemia.

The invention discloses a method for making fruit-vegetable soybean milk powder from soybean sprout. The method comprises two steps of preparing raw materials and preparing the soybean milk powder. The soybean sprout is taken as a base material; fruit-vegetable powder, functional sweeteners, a flavoring agent, a thickening agent and the like are added into the base material to prepare the soybean powder; the amino acid content and the protein solubility of the soybean powder are improved, and the pepsin digestibility is remarkably improved; and the fruit-vegetable powder contains rich essential ingredients (such as vitamins and mineral elements) and physiologically active ingredients of a human body, and has nutrition functions of remarkably regulating blood lipid, reducing plasma cholesterol, regulating a fasting insulin level, modifying blood sugar generation reaction, improving large intestine functions, prompting intestinal tract movement, reducing the contact time of harmful substances with the intestine so as to effectively prevent and cure colon cancer, and enhancing the immunologic function of human bodies. The method for making the fruit-vegetable soybean milk powder from the soybean sprout can meet the requirements of vast patients on various selections of diabetes treatment.

The present invention provides methods for treating lipid-related diseases and disorders, e.g., hyperlipidemia, hyper-triglyceridemia, hypercholesterolemia, cardiovascular disease, obesity, and type II diabetes, and for modulating lipid biosynthesis, lipid transport, plasma triglyceride levels and/or plasma cholesterol levels, by modulating the expression or activity of PGC-1β. Methods for identifying compounds which are capable of treating or preventing a lipid-related disease or disorder are also described.

The invention relates to the use of piperic acid ester compound in preparation of drug or healthcare product for reducing blood fat, wherein R1, R2, R3 are defined in the description, the piperic acid ester compounds represented by formula (1) have the actions of substantially reducing cholesterin, triglyceride and increasing high density lipoprotein, fully activating lecithin cholesterol acyl transferase, forwarding extra-hepatic tissue cholesterol to liver, cleaning out plasma lipoproteins, plasma cholesterol and cholesterol esters, thus can be applied to the prevention and treatment of cardiovascular and cerebrovascular diseases, cerebrovascular, coronary artery and peribiliary vessel pathology and hyperlipemia.

The invention discloses an assistant lipid-lowering healthcare biscuit belonging to a healthcare food. The assistant lipid-lowering healthcare biscuit contains the following components which are measured by grams and shown in a table. The food is prepared for the hyperlipemia crowd to eat, reduces the concentration of plasma cholesterol, changes the concentration of fatty acid in the blood, has the function for decreasing the triglyceride of the hyperlipemia crowd, maintains the health and the elasticity of the arterial vessels, protects the angiocarpy, lowers the incidence of a coronary heartdisease and favorably integrates functions, convenience, recreation, and the like into a whole.

The invention provides health-care oil and belongs to edible oil. The health-care oil is prepared by mixing fish oil and vegetable oil, wherein the fish oil accounts for 3 to 60 percent of the weight of the vegetable oil; and the vegetable oil is one or more of sunflower seed oil, olive oil, sesame oil, cottonseed oil, coconut oil, tea seed oil, rice bran oil, linseed oil, safflower oil, walnut oil, grape seed oil and pumpkin seed oil. In the health-care oil, the fish oil and the vegetable oil are mixed; and in the cooking process, the fish oil is added into food, so that the fish oil can be convenient to ingest and also can be accepted easily by old people and children, and the problem of forgetting eating is also solved simultaneously. Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in the fish oil can improve the cranial capacity and enhance the memory and comprehension of the children. For the old people, atherosclerosis can be retarded, hypercholesterolemia, plasma cholesterol and triglyceride can be reduced, and plasma lipoprotein concentration, blood viscosity and blood pressure can be reduced.

A method prevents or treats diseases associated with high plasma cholesterol levels. In addition, this method reduces plasma cholesterol levels. The method comprises administering a lipase inhibitor, e.g. orlistat, and a pharmaceutically acceptable bile acid sequestrant.

Health benefits from low n-6:n-3 fatty acid (FA) ratio on cardiovascular risk have been shown. However, the impact of the source of n-3 FAs has not been fully investigated. Our purpose was to investigate cardiovascular benefits of oils with a low ratio of n-6:n-3 FAs, but different sources of n-3 FAs. Mice were divided into 3 groups (n=7) and fed a diet supplemented with either a fish or flaxseed oil-based ‘designer oils’ with an approximate n-6:n-3 FA ratio of 2/1 or with a safflower-oil-based diet with a ratio of 25/1, for 16 weeks. Plasma lipids and fatty acid profile of the liver and heart tissues were characterized. Plasma cholesterol levels were reduced in both fish and flax groups by 27% and 36%, respectively, as compared to controls at endpoint. The levels of EPA and DHA in liver phospholipids were significantly increased in both fish and flax groups as compared to the control group, with more profound increases in the fish group. Arachidonic acid levels were similarly decreased in the liver tissues from both fish and flax groups as compared to controls. Our data indicates that health benefits may be achieved by lowering dietary n-6:n-3 FA even in a high fat diet medium.

The invention relates to the technical field of health care products, in particular to a blood fat-reducing and slimming tea, which is made of the following raw materials in parts by mass: 20-30 parts of sweet-scented osmanthus, 20-30 parts of poria cocos, 18-28 parts of sealwort, and 18-28 parts of Yu Liren , 16-24 parts of hawthorn, 16-24 parts of medlar, 14-20 parts of seabuckthorn, 14-20 parts of red yeast rice, 10-20 parts of hair holly, 5-15 parts of ganoderma lucidum, 5-15 parts of garcinia cambogia, lotus 5-15 parts of leaves, 5-15 parts of kudzu root, 5-7 parts of schisandra, 5-7 parts of Eucommia, 5-7 parts of Codonopsis, 5-7 parts of Tribulus terrestris, 3-5 parts of Tribulus terrestris, 3-5 parts of Smilax, 1-3 parts of Jiexianghua, 1-3 parts of Duanganwujia. The blood fat-lowering slimming tea of ​​the present invention can help digestion with the stomach, prevent the sticky grease from being blocked in the stomach first, and reduce the accumulation of fat in the upper body; flavonoids such as hawthorn flavonoids can inhibit the synthesis of liver cholesterol, and promote the liver to plasma cholesterol. It can also reduce the risk of atherosclerosis and prevent the occurrence and development of atherosclerosis.

The invention discloses a 3,4-diarylmaleimide derivative and a preparation method as well as application thereof. The general formula of the 3,4-diarylmaleimide derivative is shown in the specification. The 3,4-diarylmaleimide derivative can be applied to treating or preventing atherosclerosis or reducing plasma cholesterol level, has higher plasma cholesterol reduction activity and has broader market prospect.

The invention relates to application of hydrogen-saturated normal saline in preparation of a medicine for treating a hyperlipidemia disease, and further provides application of a hydrogen-containing oral solution in preparation of a blood fat lowering health care product. The invention develops a new usage of the saturated normal saline, wherein a hyperlipidemia mesocricitus auratus model is employed; after the saturated normal saline is injected to an abdominal cavity for four weeks, blood is taken to detect content of plasma cholesterol; a result of experiments shows that a hydrogen treatment group is obviously reduced in both plasma TC (Total Cholesterol) and LDL-C (Low Density Lipoprotein Cholesterin). The hydrogen normal saline is simple in preparation, high in injection density, convenient for use and free from explosion risk, very low in cost, and free from side effects; and a result of animal experiments shows that the hydrogen-saturated normal saline has excellent treatment advantage and can greatly reduce side effect risk of hyperlipidemia patients and greatly lower medical cost.

A method and composition for reducing the cholesterolemic effect in mammals of ingesting a blended nutritional fat composition containing a palm mid-fraction (PMF) hardstock fat combined with an unsaturated vegetable oil. The composition is solid or semi-solid at 20° C. and fluid at 35° C., and includes between 15% and 45% by weight linoleic acid. The weight ratio of disaturated triglyceride (DST) molecules to trisaturated triglyceride (TST) molecules is greater than 10:1, and the PMF hardstock fat contains approximately 50% to 95% by weight DST molecules, the majority of which contain either palmitic acid or a combination of palmitic and stearic acids at the sn-1 and sn-3 triglyceride positions and either oleic acid or linoleic acid at the sn-2 molecular position.

A method and composition for reducing the cholesterolemic effect in mammals of ingesting a blended nutritional fat composition containing a palm mid-fraction (PMF) hardstock fat combined with an unsaturated vegetable oil. The composition is solid or semi-solid at 20° C. and fluid at 35° C., and includes between 15% and 45% by weight linoleic acid. The weight ratio of disaturated triglyceride (DST) molecules to trisaturated triglyceride (TST) molecules is greater than 10:1, and the PMF hardstock fat contains approximately 50% to 95% by weight DST molecules, the majority of which contain either palmitic acid or a combination of palmitic and stearic acids at the sn-1 and sn-3 triglyceride positions and either oleic acid or linoleic acid at the sn-2 molecular position.